Tous Actualités
Suivre
Abonner Occlutech GmbH

Occlutech GmbH

Occlutech obtains favourable ruling in proceedings initiated by AGA Medical

Jena (ots)

Occlutech GmbH today announced that it had defeated a
request for insolvency, launched at the Amtsgericht Gera in Germany 
by its US competitor AGA Medical.
The request by AGA was based on wrongful assumptions about 
Occlutech, and AGA announced that it had started the said request to 
recover damages. However, the court - Amtsgericht Gera in Germany - 
stated, that a proceeding regarding any damages has not yet been 
started.
"Occlutech intends to maintain a healthy business in vascular 
intervention based on excellent products for cardiac occlusion as 
well as coronary and peripheral intervention. We have de-veloped a 
new range of innovative occluders for treating PFO and ASD in order 
not to violate the recent German patent ruling," said Tor Peters who 
was appointed CEO in late January and continued: "We expect to be on 
the market shortly with the new version."
Occlutech won against AGA Medical in the Patent Court in The Hague
in October last year. AGA Medical appealed against this decision by 
the Patent Court in The Hague and the proceeding is pending.
In Germany, AGA Medical won a patent infringement litigation 
before the appeal court in Düsseldorf. This decision has no relevance
outside Germany though.
"Our response to this is threefold," said Tor Peters. "First we 
decided to appeal the court's decision and initiated a complaint 
against the appeal court's revision-disallowance. The appeal court's 
decision is therefore not final, contrary to what was indicated by 
our competitor. Secondly, we are pursuing invalidation proceedings to
invalidate the relevant AGA Medical patent. The case will be heard in
Munich in September. Thirdly, we have developed a version of the 
occluder that does not violate any ruling. This occluder will be 
launched in Germany before the summer. Manufacturing, development, 
marketing and sales outside of Germany have not been impacted and 
will remain unchanged."
Occlusion devices are used to treat structural heart disease, 
including structural heart defects and abnormalities such as Atrial 
Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired 
channel between the heart's two atria, present in up to 25% of the 
population), in minimally invasive, non-surgical procedures. The 
market for PFO occluders is expected to expand significantly as the 
link between PFO and stroke, that is the third most common cause of 
death, as well as severe migraine becomes increasingly well 
documented.
Contact:

Pressekontakt:

Tor Peters
tor.peters@occlutech.se
Tel.: +46 42 33 65 20

Katrin Biedermann
katrin.biedermann@occlutech.de
Tel.: +49 3641 67 51 20